Enzyme's movement may be key to new cancer drugs

17-May-2018 - Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research. Not only must the kinase have all needed parts in place, the enzyme must move in the correct manner and at the correct speed ...

New targets for approved cancer drug discovered

11-Oct-2017 - Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently. A team of researchers at Moffitt Cancer ...

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

03-Aug-2015 - arGEN-X N.V. and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. The license agreement has arisen from a ...

Temple scientists target DNA repair to eradicate leukemia stem cells

12-Dec-2012 - Despite treatment with imatinib, a drug that targets chronic myeloid leukemia (CML, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression ...

Novartis drug Tasigna recommended for approval in European Union for newly diagnosed Ph+ chronic myeloid leukemia

28-Sep-2010 - Novartis has received a positive opinion recommending European Union approval of Tasigna® (nilotinib), a selective targeted therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The Committee for Medicinal Products ...

Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML

31-Aug-2010 - Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since ...

FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients

22-Jun-2010 - Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. With this approval, Tasigna becomes the first new ...

Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients

04-Jun-2010 - Novartis announced 18-month results (median follow-up) showing that Tasigna® (nilotinib) significantly surpasses Glivec® (imatinib) in slowing disease progression in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. This ...

Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia

Study results show Tasigna exceeds Glivecin every measure of efficacy in the trial including prevention of disease progression at 12 months

23-Feb-2010 - Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is ...

Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind

11-Jan-2010 - Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec). Gleevec, one of the ...